EUVIMEDEUVIMED entdecken
EditorialKommentar

Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights

Giandomenico Disabato iD, Andrea Attanasio, Gianluigi Guida, Massimo Piepoli iD

European Journal of Preventive Cardiology · 2024

DOI: 10.1093/eurjpc/zwae133 ↗

Kurz gefasst

Editorial in der Zeitschrift European Journal of Preventive Cardiology, 2024. Verfasst von Giandomenico Disabato und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This editorial refers to ‘Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study’, by A. Aimo et al., https://doi.org/10.1093/eurjpc/zwae093. Transthyretin cardiac amyloidosis (CA) (ATTR-CA) is a progressive cardiomyopathy characterized by the deposition of transthyretin (TTR) amyloid fibrils in the myocardium, leading to heart failure.1 The main types of TTR CA are hereditary (ATTRv-CA), in which a pathogenetic TTR variant is identified, and wild-type, where no variant is identified (ATTRwt-CA).1 The median survival of ATTRwt-CA patients without disease-modifying therapy has been reported as 3.6 years.2 Grogan et al.2 proposed a staging system based on troponin T levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP), which delineates three stages with different prognoses: median survival for stages I, II, and III were 66, 40, and 20 months, respectively. Recent advancements in the treatment of ATTRwt-CA have been achieved with the introduction of tafamidis. Clinical trials3 have demonstrated that tafamidis significantly reduces mortality and cardiovascular-related hospitalizations while also mitigating the decline in functional capacity and improving quality of life compared with placebo. Significant progress has been achieved in diagnosing ATTRwt-CA, particularly in establishing non-invasive diagnostic criteria that avoid the need for biopsy confirmation of amyloid fibrils, as reported by Gilmore et al.’s4 study. Although ATTRwt-CA has historically been considered a rare disease, recent studies have questioned this classification, especially in older individuals with heart failure symptoms and ‘red flag’ signs of CA.5 Thus, according to European Union Policy, a disease is considered rare when affecting fewer than 5 people out of every 10 000 individuals.6 No comprehensive data on the prevalence and incidence of CA have been published systematically, and data are obsolete. Gilstrap et al.7 conducted a retrospective analysis in the USA, reporting an incidence rate of 17 per 100 000 person-years and a prevalence rate of 55 per 100 000 person-years among hospitalized patients for heart failure. The prevalence of CA is associated with various cardiac diseases,5 resulting in potential fluctuations in specific clinical scenarios. For instance, it is noted as 8% in aortic stenosis, 7% in hypertrophic cardiomyopathy, 12% in heart failure with preserved ejection fraction, and 10% in heart failure with reduced ejection fraction. A study conducted by Aimo et al.8 aimed to redefine the prevalence and incidence of CA among individuals in the general population over 65 years old. The study used a double-step approach to identify individuals at high risk for CA. The approach enabled the diagnosis of four cases of ATTRwt-CA, indicating a possible higher prevalence and incidence of CA rates than those reported in the literature. However, due to the limited sample size of this study, definitive conclusions about prevalence cannot be drawn. Despite this limitation, the study offers valuable insights, stressing the need for further prevalence and incidence studies to reevaluate the classification of ATTRwt-CA as a rare disease, given its significant treatment economic burden. The potential of identifying CA risk through cost-effective serum biomarkers, such as NT-proBNP and high-sensitivity troponin, accessible in non-specialized centres, underscores the importance of early screening efforts. Ongoing scientific research is being conducted to determine the actual prevalence and incidence of CA in individuals who are considered at high risk based on scientific literature. However, further studies are needed to understand if the current diagnostic tools are effective in identifying asymptomatic subjects without any clinical risk factors. These efforts aim to administer tafamidis therapy earlier, a drug that has the potential to improve the prognosis of the disease and alter its natural history. This drug is most effective when administered in the earlier stages of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansPrevalencePrealbuminMutationGenetic Predisposition to Disease

Substanzen

TTR protein, humanPrealbumin

Autor:innen und Institutionen

  • Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy.
  • Multimodality Cardiac Imaging Unit, IRCCS Policlinico San Donato, Via Morandi 30, Milan 20097, Italy.
  • Department of Preventive Cardiology, Wroclaw Medical University, Wroclaw, Poland.

ORCID-Profile: Giandomenico Disabato, Massimo Piepoli

Zitieren

APA

Disabato, G., Attanasio, A., Guida, G., & Piepoli, M. (2024). Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae133

Vancouver

Disabato G, Attanasio A, Guida G, Piepoli M. Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights. European Journal of Preventive Cardiology. 2024. doi:10.1093/eurjpc/zwae133

BibTeX
@article{Disabato2024,
  author = {Disabato, Giandomenico and Attanasio, Andrea and Guida, Gianluigi and Piepoli, Massimo},
  title = {Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights},
  journal = {European Journal of Preventive Cardiology},
  year = {2024},
  doi = {10.1093/eurjpc/zwae133}
}
Kostenlos starten →